E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Human Immunodeficiency Virus-1 |
|
E.1.1.1 | Medical condition in easily understood language |
|
E.1.1.2 | Therapeutic area | Diseases [C] - Virus Diseases [C02] |
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 20.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10020443 |
E.1.2 | Term | Human immunodeficiency virus syndrome |
E.1.2 | System Organ Class | 100000004862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To assess, as part of the acceptability, the ability to swallow the 600/90 mg DRV/COBI FDC tablet dispersed in water |
|
E.2.2 | Secondary objectives of the trial |
- To assess, as part of acceptability, the ease of swallowing, the palatability, and the ease of dispersion of the 600/90 mg DRV/COBI FDC tablet dispersed in water - To assess the acceptability of the intake of the 600/90 mg DRV/COBI FDC tablet dispersed in water, if to be taken daily - To evaluate short-term safety and tolerability of the 600/90 mg DRV/COBI FDC tablet dispersed in water |
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
Each potential participant must satisfy all of the following criteria to be enrolled in the study: 1. 3 years or older. 2. Has documented chronic HIV-1 infection. 3. Must be on an allowed stable unchanged ARV regimen for at least 3 months prior to screening. 4. Has a documented plasma HIV-1 RNA <400 copies/mL within 6 months prior to or at screening. 5. Must be able to comply with the protocol requirements (willing to attempt swallowing of tablets dispersed in water, and to adhere to prohibitions and restrictions specified in this protocol). 6. Must be in a condition that allows to perform the protocol-specified assessments and so must his/her caregiver, if applicable. If a participant and his or her caregiver have difficulties in completing the questionnaire, the study-site personnel may assist. 7. Body weight within ≥15 kg to <25 kg. 8. Parent(s) (preferably both if available or as per local requirements) or their legally acceptable representative must sign an ICF indicating that they understand the purpose of, and procedures required for, the study and is/are willing to allow the child to participate in the study. Assent is also required of children capable of understanding the nature of the study (typically 7 years of age and older). |
|
E.4 | Principal exclusion criteria |
Any potential participant who meets any of the following criteria will be excluded from participating in the study: 1. Known allergies, hypersensitivity, or intolerance to DRV/COBI or any excipient of the study intervention. 2. Has taken any disallowed therapies. 3. Any active condition (eg, active oral infection [candidiasis], significant physical or psychological disease or other findings during screening) that could prevent the participant from swallowing dispersions in water, or for which, in the opinion of the investigator, participation would not be in the best interest of the participant (eg, compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments and outcomes. 4. Active acquired immunodeficiency syndrome (AIDS)-defining illness at screening. 5. Has had any contact with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) positive or Coronavirus Disease 2019 (COVID-19) patients within the last 2 weeks prior to admission to the clinical research center. 6. Participant is a family member of an employee of the investigator or study site, with direct involvement in the proposed study or other studies under the direction of that investigator or study site, or is a family member of an employee of Johnson & Johnson. |
|
E.5 End points |
E.5.1 | Primary end point(s) |
Ability to take the 600/90 mg DRV/COBI FDC tablet dispersed in water, derived from a questionnaire to be completed by the observing site personnel
|
|
E.5.1.1 | Timepoint(s) of evaluation of this end point |
|
E.5.2 | Secondary end point(s) |
For the 600/90 mg DRV/COBI FDC tablet dispersed in water: - Ease of swallowing, assessed using a questionnaire to be completed by the participant and a questionnaire to be completed by the caregiver - Palatability assessed using a questionnaire to be completed by the participant and a questionnaire to be completed by the caregiver - Ease of dispersion assessed using a questionnaire to be completed by the caregiver - Acceptability, if to be taken daily, using a questionnaire to be completed by the participant and a questionnaire to be completed by the caregiver - Assessment of adverse events |
|
E.5.2.1 | Timepoint(s) of evaluation of this end point |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | No |
E.6.2 | Prophylaxis | No |
E.6.3 | Therapy | No |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | No |
E.6.6 | Pharmacokinetic | No |
E.6.7 | Pharmacodynamic | No |
E.6.8 | Bioequivalence | No |
E.6.9 | Dose response | No |
E.6.10 | Pharmacogenetic | No |
E.6.11 | Pharmacogenomic | No |
E.6.12 | Pharmacoeconomic | No |
E.6.13 | Others | Yes |
E.6.13.1 | Other scope of the trial description |
Acceptability of DRV/COBI FDC tablet for oral use |
|
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Yes |
E.7.1.1 | First administration to humans | No |
E.7.1.2 | Bioequivalence study | No |
E.7.1.3 | Other | Yes |
E.7.1.3.1 | Other trial type description |
|
E.7.2 | Therapeutic exploratory (Phase II) | No |
E.7.3 | Therapeutic confirmatory (Phase III) | No |
E.7.4 | Therapeutic use (Phase IV) | No |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | No |
E.8.1.2 | Open | Yes |
E.8.1.3 | Single blind | No |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | No |
E.8.1.6 | Cross over | No |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.2.4 | Number of treatment arms in the trial | 1 |
E.8.3 |
Will this trial be conducted at a single site globally?
| No |
E.8.4 | Will this trial be conducted at multiple sites globally? | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.2 | Trial being conducted completely outside of the EEA | No |
E.8.6.3 | Specify the countries outside of the EEA in which trial sites are planned |
South Africa |
United States |
|
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.2 | In all countries concerned by the trial months | 9 |
E.8.9.2 | In all countries concerned by the trial days | 0 |